ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silvr, unless this was intentional, they need a better IR personnel working on messaging. They could of easily stated that we are raising guidance, based on our core business not, the short term bumps we get from filling voids such as short term shortages, as Q2 guidance was for an average of $105.5 million in Revenue per remaining quarter (mid-guidance) to $117.6 million for Q4. Though we are not ready to give guidance for 2024, we feel confident enough in our revenue growth to invest in an expansion the New Jersey plant coming on line in Q1 2024. I bet that would have garnered a much different market reaction.